The Multifactorial Pathogenesis of Calciphylaxis: A Case Report.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
07 Jun 2021
07 Jun 2021
Historique:
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
10
6
2021
Statut:
epublish
Résumé
BACKGROUND Calciphylaxis is a rare and lifethreatening syndrome characterized by small vascular calcifications, which lead to the occlusion of blood vessels and painful skin lesions with tissue necrosis. Although the disease can develop in a population without kidney failure, it is typically detected in patients receiving dialysis, with an increasing frequency ranging from 1% to 4%. Therefore, the disease is also known as calcific uremic arteriolopathy. The prognosis in patients with coexisting chronic kidney disease is very poor, with a 1-year mortality rate of up to 80%. Numerous risk factors for calciphylaxis have been described, such as obesity, diabetes mellitus, female sex, White race, overuse of calcium and vitamin D supplements, and vitamin K deficiency. The disease is often accompanied by disorders such as hyperphosphatemia, elevated parathyroid hormone level, and a deficiency of natural calcification inhibitors, such as fetuin-A and matrix Gla protein. However, not all patients with calciphylaxis have the abnormalities described above, suggesting that the pathogenesis of calciphylaxis is multifactorial and unfortunately still uncertain. CASE REPORT We report a case of calciphylaxis in a 52-year-old White woman with multiple comorbidities and on chronic hemodialysis treatment, who presented with severe subcutaneous painful nodules and necrotic ulcers on both legs. CONCLUSIONS Although the prognosis of this rare and underrecognized disease is poor, an early diagnosis and interdisciplinary treatment including pain relief, wound care, appropriate nutritional support, correction of mineral parameters, administration of sodium thiosulphate, and adequate hemodialysis therapy can improve patient quality of life.
Identifiants
pubmed: 34097671
pii: 930026
doi: 10.12659/AJCR.930026
pmc: PMC8197444
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e930026Références
Perm J. 2011 Spring;15(2):85-7
pubmed: 21841931
N Engl J Med. 2018 May 03;378(18):1704-1714
pubmed: 29719190
Oxid Med Cell Longev. 2010 Mar-Apr;3(2):109-21
pubmed: 20716935
J Clin Aesthet Dermatol. 2008 Jul;1(2):38-41
pubmed: 21103322
Am J Kidney Dis. 2015 Jul;66(1):133-46
pubmed: 25960299
Can Med Assoc J. 1961 Sep 30;85:770-6
pubmed: 13749961
Kidney Blood Press Res. 2013;37(4-5):346-59
pubmed: 24247072
J Clin Aesthet Dermatol. 2013 May;6(5):41-4
pubmed: 23710271
J Am Acad Dermatol. 2007 Apr;56(4):569-79
pubmed: 17141359
Int J Nephrol. 2011 Feb 24;2011:701603
pubmed: 21423552
Cutis. 2018 Dec;102(6):395-400
pubmed: 30657805
J Nephrol. 2011 Mar-Apr;24(2):142-8
pubmed: 21337312
Cases J. 2008 Sep 23;1(1):178
pubmed: 18811973
Clin J Am Soc Nephrol. 2008 Jul;3(4):1139-43
pubmed: 18417747